A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
Clinical trial NCT06283212 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06283212
- Sponsor
- Encoded Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-09
- Primary completion
- 2030-10-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.